Integrating ADNI results into Alzheimer's disease drug development programs.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is providing critical new information on biomarkers in cognitively normal elderly, persons with mild cognitive impairment (MCI), and patients with mild Alzheimer's disease (AD). The data provide insights into the progression of the pathology of AD over time, assist in understanding which biomarkers might be most useful in clinical trials, and facilitate development of disease-modifying treatments. ADNI results are intended to support new AD treatment development; this report considers how ADNI information can be integrated in AD drug development programs. Cerebrospinal fluid (CSF) amyloid beta protein (Abeta) measures can be used in Phase I studies to detect any short term effects on Abeta levels in the CSF. Phase II studies may benefit most from biomarker measures that can inform decisions about Phase III. CSF Abeta levels, CSF total tau and phospho-tau measures, fluorodeoxyglucose positron emission tomography (FDG PET), Pittsburgh Compound B (PIB) amyloid imaging, or magnetic resonance imaging (MRI) may be employed to select patients in enriched trials or as outcomes for specific disease-modifying interventions. Use of biomarkers may allow Phase II trials to be conducted more efficiently with smaller populations of patients or shorted treatment times. New drug applications (NDAs) may include biomarker outcomes of phase III trials. ADNI patients are highly educated and are nearly all of Caucasian ethnicity limiting the generalizability of the results to other populations commonly included in global clinical trials. ADNI has inspired or collaborates with biomarker investigations worldwide and together these studies will provide biomarker information that can reduce development times and costs, improve drug safety, optimize drug efficacy, and bring new treatments to patients with or at risk for AD.
Cummings
Jeffrey L
JL
Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7226, United States. jcummings@mednet.ucla.edu
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000188:drug therapy*; D000818:Animals; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic / Q000639:trends; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000639:trends; D049268:Positron-Emission Tomography / Q000639:trends
D015415:Biomarkers
Neuroimage. 2008 Nov 15;43(3):458-69
18691658
J Neurosci. 2007 Oct 10;27(41):10957-68
17928437
Arch Neurol. 1999 Mar;56(3):303-8
10190820
Neurology. 2009 Dec 15;73(24):2061-70
19923550
Alzheimers Dement. 2008 Jul;4(4):255-64
18631976
Arch Neurol. 2009 Mar;66(3):382-9
19273758
Arch Neurol. 2006 May;63(5):674-81
16682537
Radiology. 2009 Apr;251(1):195-205
19201945
AAPS J. 2007 Mar 23;9(1):E105-8
17408233
Adv Exp Med Biol. 2009;655:1-12
20047030
Neurology. 2005 May 10;64(9):1553-62
15883316
Neurology. 2005 May 10;64(9):1563-72
15883317
Hippocampus. 2009 Jun;19(6):579-87
19437497
Neuroimage. 2008 Aug 1;42(1):19-27
18547819
J Alzheimers Dis. 2009;16(2):235-70
19221415
NeuroRx. 2004 Apr;1(2):189-95
15717019
J Am Geriatr Soc. 2008 Aug;56(8):1424-33
18662209
Lancet Neurol. 2008 Sep;7(9):779-86
18672400
Brain. 2008 Jun;131(Pt 6):1630-45
18339640
Toxicology. 2008 Mar 20;245(3):219-23
18280028
Science. 2009 Oct 16;326(5951):386-9
19833956
Lancet Neurol. 2007 Aug;6(8):734-46
17616482
J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38
16306154
Ann Neurol. 2009 Apr;65(4):403-13
19296504
Dement Geriatr Cogn Disord. 2006;22(4):312-9
16940725
Neurology. 2010 Jan 19;74(3):201-9
20042704
Neuroscience. 2000;95(3):721-5
10670438
Brain. 2009 Aug;132(Pt 8):2036-47
19439419
Eur Radiol. 2010 Mar;20(3):674-82
19760240
J Nucl Med. 2009 Nov;50(11):1887-94
19837759
Alzheimers Dement. 2010 Jan;6(1):39-53
19592311
Alzheimers Dement. 2009 Sep;5(5):406-18
19751920
Clin Neuropharmacol. 2007 Nov-Dec;30(6):317-25
18090456
Arch Neurol. 2008 Aug;65(8):1031-8
18695053
Neurology. 2007 Oct 16;69(16):1622-34
17938373
Magn Reson Med. 2009 Aug;62(2):365-72
19526493
Neuroimage. 2009 Oct 1;47(4):1506-13
19477282
Neuroimage. 2009 Feb 15;44(4):1415-22
19027862
Annu Rev Pharmacol Toxicol. 2008;48:631-51
17937595
Exp Gerontol. 2009 Sep;44(9):579-85
19539742
Neurology. 2009 Oct 13;73(15):1193-9
19822868
N Engl J Med. 2009 Feb 19;360(8):816-23
19228627
Ann N Y Acad Sci. 2009 Oct;1180:36-46
19906259
Clin Neuropharmacol. 2010 Mar-Apr;33(2):74-8
19935404
Brain. 2009 May;132(Pt 5):1355-65
19339253
Neuroimage. 2009 Mar;45(1 Suppl):S3-15
19041724
J Neurol. 2009 Aug;256(8):1288-95
19353221
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S15-20
18631992
Neuroimage. 2008 May 15;41(1):19-34
18378167
Neuroimage. 2009 May 1;45(4):1107-16
19349228
Neurobiol Aging. 2011 Jul;32(7):1207-18
19660834
Alzheimers Dement. 2009 Mar;5(2):108-13
19328437
Arch Neurol. 2001 Dec;58(12):1985-92
11735772
J Neurochem. 2007 Feb;100(3):802-9
17156133
Biochim Biophys Acta. 2010 Apr;1802(4):373-88
20060898
Neurology. 2009 Jul 28;73(4):287-93
19636048
J Neurosci. 2001 Jan 15;21(2):372-81
11160418
Neuroimage. 2010 Jun;51(2):586-98
20206704
Int Psychogeriatr. 2009 Aug;21(4):672-87
19470201
Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):292-9
18090435
Alzheimers Dement. 2009 Sep;5(5):388-97
19751918